Adaptive Biotechnologies: Revolutionizing Immune-Driven Medicine Adaptive Biotechnologies is a publicly traded company (NASDAQ: ADPT) pioneering the field of immune-driven medicine. Our flagship product, clonoSEQ, is an FDA-authorized test for detecting and monitoring minimal residual disease (MRD) in patients with select blood cancers, significantly impacting cancer treatment decisions. We leverage the power of the adaptive immune system to transform disease diagnosis and treatment, setting a new standard for precision medicine. Our work relies on a robust technological foundation. We utilize a modern tech stack including Amazon Web Services, Microsoft Azure, and Cloudflare, enabling a scalable and secure infrastructure for our innovative bioinformatics pipelines. Our engineering culture embraces automation (via Ansible) and DevOps practices, ensuring efficient and high-quality software delivery. We prioritize collaboration and innovation, fostering a dynamic environment where engineers directly contribute to improving patient outcomes. Adaptive Biotechnologies offers a remote-friendly work environment, allowing talented individuals to contribute from various locations. We are committed to building diverse, equitable, and inclusive teams and pride ourselves on a culture of collaboration and continuous learning. Our continued growth and significant funding demonstrate our commitment to advancing immune medicine and improving patient lives. Join us in shaping the future of healthcare. With over 500 employees and continued expansion, Adaptive Biotechnologies offers numerous growth opportunities in a fast-paced, impactful environment.